MUSC Hollings Cancer Center confirms e-cigarettes have some value for smoking cessation

Recent research from the MUSC Hollings Cancer Center shows that e-cigarettes have some value as a smoking cessation aid.

This study is significant as it supports the role of e-cigarettes in reducing smoking or quitting in real-world settings (i.e., without detailed guidance or additional cessation support).

This is the largest e-cigarette trial in the U.S., showing that the use of e-cigarettes helps traditional cigarette users on their path to quitting, even including those who initially expressed no desire to quit. The results were published this month in the journal Clinical E-Medicine.

However, Matthew Carpenter, co-leader of the cancer control research project at the Hollings Cancer Center and the first author of the paper, warned, "This is not a magic bullet for quitting smoking." This study involved participants from 11 cities across the U.S. and lasted four years.

The question of whether e-cigarettes are a viable option for quitting smoking is a contentious one, with different countries taking different approaches.

The latest research shows that those who smoke e-cigarettes are more likely to completely quit combustible tobacco. They are also more likely to reduce the number of cigarettes smoked daily.

The study selected the NJOY Ace e-cigarette because it was chosen as the standardized research e-cigarette (SREC) product by the National Institute on Drug Abuse (NIDA) for research. This means that Ace is now a standardized product that will be used in other laboratory studies.